Amlodipine Cost in Iowa 2026: Cash Prices, Medicaid, Insurance, and Discount Programs

What Does Amlodipine Actually Cost at Iowa Pharmacies in 2026?

The out-of-pocket cash price for generic amlodipine at Iowa retail pharmacies is approximately $8 per month for a 30-day supply of 5 mg tablets. That figure reflects widespread generic competition following patent expiration of Pfizer's Norvasc. The branded version carries a list price near $80/month, though almost no cash-pay patient pays that amount. FDA labeling for amlodipine besylate confirms the drug is available in 2.5 mg, 5 mg, and 10 mg oral tablet strengths, all of which are off-patent and generically manufactured.

Prices vary by pharmacy chain and location. A 30-day supply at a large Iowa chain such as Hy-Vee Pharmacy or CVS typically runs between $6 and $12 without insurance. Walmart's $4/$10 generic program lists amlodipine as a qualifying drug, bringing the cost to $10 for a 90-day supply, roughly $3.33 per month, for patients who shop there. Independent pharmacies in rural Iowa may charge slightly more, generally $10, $18/month, because they lack the purchasing volume of national chains.

Amlodipine is a calcium channel blocker whose efficacy in reducing cardiovascular events is well-documented. The ASCOT-BPLA trial (Lancet 2005, N=19,257) compared amlodipine-based therapy against atenolol-based therapy in hypertensive patients. The amlodipine arm produced a 10% relative reduction in the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease (P<0.0001), and the trial was stopped early at a median 5.5 years because of a significant mortality benefit in the amlodipine group. That evidence base underpins amlodipine's near-universal listing on insurance formularies, which in turn keeps demand high and generic prices low.

The American College of Cardiology / American Heart Association 2017 hypertension guideline recommends thiazide diuretics, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers, a class that includes amlodipine, as first-line agents for most adults. Amlodipine's once-daily dosing and long 30 to 50 hour half-life make adherence straightforward.

Does Iowa Medicaid Cover Amlodipine?

Iowa Medicaid does not currently list amlodipine on its preferred drug list (PDL) as a preferred agent, meaning standard prior authorization is required before the program will pay for a claim. Iowa Medicaid's PDL is maintained by Iowa Health and Human Services and is updated quarterly; the Iowa Department of Health and Human Services pharmacy program page outlines the current PDL and prior authorization request process.

Prior authorization is not an automatic denial. A prescriber can submit a PA request demonstrating medical necessity, and approval rates for established antihypertensives are reasonably high when documentation is complete. Patients enrolled in Iowa Medicaid managed care plans, Molina Healthcare of Iowa, HHSC AmeriHealth Caritas Iowa, or Iowa Total Care, should check their specific plan formulary, since managed care contracts may differ from the base PDL.

Iowa Medicaid does cover several other calcium channel blockers on a preferred basis, and a prescriber may substitute one of those if PA for amlodipine is denied. However, for most low-income patients in Iowa, the $8/month cash price makes out-of-pocket payment a practical alternative to navigating PA paperwork for this specific drug.

Patients aged 65 and older enrolled in Medicare Part D will find amlodipine on virtually every plan's formulary, typically in Tier 1 or Tier 2, with copays ranging from $0 to $10/month. The CMS Part D formulary search tool lets Iowa residents compare plan-specific costs.

The JNC 8 guideline (JAMA 2014) explicitly recommends calcium channel blockers as first-line therapy for non-Black adults with hypertension, and amlodipine is the most studied agent in the class. That guideline position strengthens PA arguments when insurers push back.

Is Compounded Amlodipine Legal in Iowa?

Compounded amlodipine prepared by a licensed 503A pharmacy is legal in Iowa. Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a) authorizes state-licensed pharmacies to compound drug products for individual patients based on a valid prescription. Iowa Code Chapter 155A governs pharmacy practice and does not prohibit compounding of amlodipine specifically. The Iowa Board of Pharmacy regulates 503A compounders in the state and requires them to meet USP <795> standards for non-sterile preparations.

Compounded amlodipine is most commonly prepared in an oral liquid form, which is useful for pediatric patients or adults with swallowing difficulties. Some 503A pharmacies also compound topical amlodipine gel, though the FDA has flagged topical calcium channel blockers as preparations where clinical equivalence to oral dosing is not established. Prescribers should note that compounded preparations are not FDA-approved finished drug products, and bioavailability data for novel delivery forms is generally limited.

Cost of compounded amlodipine through a 503A pharmacy in Iowa may effectively be $0 for patients whose prescriber participates in programs that sponsor compounded formulations, though this arrangement varies significantly by pharmacy and prescriber relationship. Cash cost for a custom compounded oral suspension at an Iowa compounding pharmacy typically runs $20, $40/month, still below many branded alternatives.

The FDA's 503A vs. 503B compounding framework distinguishes patient-specific 503A compounding from large-scale 503B outsourcing facilities. Iowa patients receiving compounded amlodipine should confirm their pharmacy holds a current Iowa Board of Pharmacy compounding license and is not operating under a 503B model, which has different dispensing restrictions.

Which Insurance Plans Cover Amlodipine in Iowa?

Most commercial insurance plans covering Iowa residents list generic amlodipine on Tier 1 (preferred generic), resulting in copays of $0, $10/month. Iowa's largest commercial insurers, Wellmark Blue Cross Blue Shield, UnitedHealthcare, Medica, and Aetna, all include generic amlodipine on their standard formularies. Wellmark's formulary search and UnitedHealthcare's drug list portal allow members to confirm specific tier placement by entering their plan ID.

Employer-sponsored plans governed by ERISA may maintain their own formularies independent of the carrier's standard list. Employees of Iowa school districts, state agencies, and municipalities enrolled in the Iowa Employees Benefit Association (IEBA) plan should consult their plan's summary of benefits or pharmacy benefit manager (typically CVS Caremark or Express Scripts) for current tier placement.

The ACC/AHA 2017 guideline classifies amlodipine as a first-line antihypertensive, and insurers generally follow clinical guideline designations when setting formulary tiers. First-line status means amlodipine rarely requires step therapy (trying a cheaper drug first) before coverage is approved, unlike some specialty medications.

For plans that do impose a step-therapy requirement, most insurers accept a prescriber attestation that the patient previously tried a thiazide diuretic such as hydrochlorothiazide and either did not tolerate it or did not achieve target blood pressure of <130/80 mmHg per the 2017 ACC/AHA target.

High-deductible health plans (HDHPs) paired with HSAs are common among Iowa employers. Before meeting the deductible, patients on HDHPs pay the plan's negotiated rate for amlodipine, which is usually $8, $15/month at in-network pharmacies, consistent with the general Iowa cash price range.

How GoodRx, Manufacturer Cards, and Other Discount Programs Work in Iowa

GoodRx consistently offers amlodipine in Iowa at $8, $12/month at major chains and is accepted at Hy-Vee, Walgreens, CVS, Rite Aid, and most independent pharmacies statewide. GoodRx works by presenting a negotiated group purchasing rate rather than using insurance, which means patients should compare their insurance copay against the GoodRx price before choosing which to submit. GoodRx pricing data for amlodipine updates in near-real-time.

Pfizer offers a savings card for branded Norvasc, but branded Norvasc is rarely dispensed in Iowa given that generics are bioequivalent and dramatically cheaper. FDA guidance on generic drug bioequivalence confirms that approved generics must demonstrate bioequivalence within a 80 to 125% confidence interval for pharmacokinetic parameters, making substitution clinically appropriate for most patients.

NeedyMeds and RxAssist maintain databases of manufacturer patient assistance programs. Pfizer's patient assistance program (PAP) covers Norvasc for uninsured patients below 400% of the federal poverty level; Iowa residents can apply at NeedyMeds.org. Given the $8/month generic price, however, the PAP process carries administrative overhead that may not justify itself unless a patient specifically requires branded Norvasc.

The 340B Drug Pricing Program allows eligible Iowa health centers (federally qualified health centers, critical access hospitals, and Ryan White clinics) to purchase covered outpatient drugs at significant discounts and pass savings to qualifying patients. Iowa has over 30 HRSA-designated 340B-covered entities. Patients receiving care at a covered entity may access amlodipine at reduced or zero cost through the entity's in-house or contract pharmacy. The Health Resources and Services Administration maintains a searchable 340B covered entity database.

Telehealth Prescribing of Amlodipine in Iowa

Iowa law permits telehealth prescribing of amlodipine, provided the prescriber establishes a valid prescriber-patient relationship before issuing a prescription. Iowa Code § 135.173 and Iowa Administrative Code 653.13.7 govern telemedicine practice, requiring that prescribers conduct an appropriate evaluation, which may occur via synchronous audio-video, before prescribing. Iowa's telemedicine statute aligns with most state telehealth frameworks in that phone-only encounters are generally insufficient for initiating a new controlled or high-risk drug, though amlodipine is not a controlled substance.

Amlodipine is a Schedule V-exempt medication (non-controlled), so the DEA's telemedicine prescribing restrictions for controlled substances do not apply. A telehealth prescriber in Iowa must hold an active Iowa medical license or qualify for an interstate compact exemption under the Interstate Medical Licensure Compact (IMLC), of which Iowa is a member state.

HealthRX providers can evaluate Iowa patients via video visit for hypertension, assess blood pressure readings the patient provides (ideally a 7-day home average per the AHA home blood pressure monitoring guidance), and send an amlodipine prescription electronically to any Iowa pharmacy. Most Iowa pharmacies accept electronic prescriptions under Iowa's ePrescribing framework.

The ALLHAT trial (JAMA 2002, N=33,357) remains the largest antihypertensive outcomes trial ever conducted. Amlodipine's predecessor in the dihydropyridine class performed comparably to chlorthalidone on the primary composite cardiovascular endpoint (relative risk 0.98, P<0.09), supporting the use of calcium channel blockers as telehealth-initiated first-line therapy. For patients with documented left ventricular hypertrophy, diabetic nephropathy, or recurrent stroke, prescriber choice between drug classes may shift, and telehealth evaluation should include a medication history review.

Practical Price Comparison: Iowa Pharmacies in 2026

A direct comparison of amlodipine 5 mg, 30-tablet supply across Iowa access channels illustrates the full cost range patients face:

• Walmart $4 generic program: approximately $4/month (or $10 for 90 days)
• GoodRx at Hy-Vee or CVS: approximately $8, $12/month
• Commercial insurance Tier 1 copay: approximately $0, $10/month
• Iowa Medicaid (with approved PA): $0, $3/month (standard Medicaid copay after PA)
• 503A compounding pharmacy (oral liquid): approximately $20, $40/month
• Medicare Part D Tier 1: approximately $0, $10/month
• 340B covered entity: approximately $0, $2/month for qualifying patients
• Branded Norvasc without savings card: approximately $80/month

The 10-fold price gap between cash-pay generic ($8) and branded list price ($80) reflects standard generic market dynamics. The FDA's Abbreviated New Drug Application pathway, which amlodipine generics began using after patent expiration, has produced over 40 FDA-approved amlodipine generic manufacturers as of 2024, per FDA Orange Book data. That level of competition sustains low retail prices.

Patients paying more than $12/month for generic amlodipine at an Iowa pharmacy should ask the pharmacist to run a GoodRx or SingleCare coupon rather than submitting to insurance, particularly on high-deductible plans, where the negotiated discount card rate often beats the pre-deductible insurance rate.

Clinical Context: Why Amlodipine Remains a First-Line Drug in 2026

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle, producing arterial vasodilation and reducing peripheral resistance. Its 30 to 50 hour half-life means a missed dose rarely causes rebound hypertension, a property that supports adherence in real-world Iowa patient populations.

The CAMELOT trial (JAMA 2004, N=1,991) compared amlodipine 10 mg against placebo in patients with coronary artery disease and normal blood pressure. Amlodipine reduced the primary composite cardiovascular endpoint by 31% (P<0.003) compared to placebo, establishing benefit beyond blood pressure reduction alone. That angina indication explains why amlodipine holds FDA approval for both hypertension and chronic stable or vasospastic angina, as confirmed in the FDA prescribing information.

Common side effects, peripheral edema (7 to 10% of patients at 10 mg per the FDA label), flushing, and headache, are dose-dependent and generally mild. Reflex tachycardia is less pronounced with amlodipine than with shorter-acting dihydropyridines such as nifedipine IR because of the drug's slow onset of action.

Drug interactions warrant attention for Iowa patients on polypharmacy regimens. CYP3A4 inhibitors such as clarithromycin, ketoconazole, and grapefruit juice may increase amlodipine plasma concentrations. CYP3A4 inducers such as rifampin may decrease efficacy. The FDA drug interaction database provides a current reference for clinicians and pharmacists reviewing patient medication lists.

The 2023 European Society of Hypertension guidelines (J Hypertens 2023) maintain calcium channel blockers, including amlodipine, as preferred agents for isolated systolic hypertension in older adults and for patients of African or Hispanic descent, reinforcing its relevance across Iowa's changing demographic profile.